Single and Multiple Ascending Dose Study of KN-002 — KN-002

Asthma COPD Clinical Trial

Official title:
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD

Status Active, not recruiting

Clinical Trial Summary

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in subjects with stable, mild asthma; Part 3 is a repeat dose in patients with moderate to severe asthma and Part 4 is a repeat dose in patients with COPD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05006521
Study type	Interventional
Source	Kinaset Therapeutics Inc
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	July 30, 2021
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06099145` - Clinical and Medico-economic Validation of the HEPHAI Solution.	N/A
Completed	`NCT05764343` - The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases	N/A
Recruiting	`NCT06039943` - Relationship Between Acoustic Breath Sounds and Spirometry	N/A
Recruiting	`NCT05299385` - The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)	Phase 3
Active, not recruiting	`NCT04341701` - Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases	N/A
Recruiting	`NCT04233190` - A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment	Phase 3